CCRC Current Studies
Advancing COVID-19 Clinical Research
Developing effective treatment and interventions for COVID-19 requires clinical studies to test experimental medications. In addition to the current studies actively enrolling participants, the COVID-19 Clinical Research Center anticipates launching several other studies in the coming months.
All studies are led by either a Fred Hutch or University of Washington investigator. Studies may be based on science completed by biotechnology or pharmaceutical companies. Study sponsors cover all clinical trial costs and under no circumstances will a participant’s insurance be charged for any service. The CCRC is not a hospital or clinic and will only have participation from volunteers that fit the study criteria and fully consent to participation.
Interested in volunteering for one of our studies? Contact us to see if you qualify.
STOP COVID 2 – Washington University in St. Louis
Fluvoxamine for early treatment of COVID-19
Study Purpose and Summary
This is a randomized, double-blinded, placebo-controlled study to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications. This study is fully-remote, which means that there is no face-to-face contact; study materials including study drug will be shipped to participants' houses. The study will include participants with COVID-19 that are experiencing at least one related symptom, with adults that are 18-39 years of age required to have at least 1 risk factor for progression.
Eligibility Criteria
- Either:
40 years of age or older, no risk factors required
or
18 - 39 years of age who have at least one of the following risk factors for developing serious COVID-19:
is one of the following racial/ethnic groups: Black/African-American, Hispanic/Latinx, or Native American (including more than one race);
and/or has a pre-existing factor for progression: diabetes, obesity (body mass index > 30), cardiovascular disease (coronary artery disease, history of myocardial infarction, or heart failure), hypertension, chronic lung disease, immune disorder - Tested positive for SARS-CoV-2 (test occurred not more than 7 days prior to enrollment)
- Willing and able to provide written informed consent to participate
- Experiencing at least one of the following symptoms (onset no more than 10 days prior to enrollment): fever, sore throat, cough, shortness of breath upon exertion, chest pain, stuffy or runny nose, muscle pain, nausea or throwing up, diarrhea
- Are at home (not in the hospital) and have not been hospitalized for COVID-19
- Agreement to not participate in another clinical trial of an experimental treatment for COVID-19 during the study period
Other protocol-defined Inclusion/Exclusion criteria may apply.
More about this trial
Step 1: Visit ClinicalTrials.gov, identifier NCT04668950, to determine if this study is right for you.
Step 2: If you are interested in volunteering, complete our online survey or contact us by phone or email.
REGN-COV2 - Regeneron Pharmaceuticals
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With SARS-CoV-2 Infection
Study Purpose and Summary
The REGN 2067 study is testing an infusion of REGN-COV2, a combination of two antibodies against SARS-CoV-2, the virus that causes COVID-19, to see whether they can: (1) decrease the amount of virus in the body; (2) decrease the length of time the virus is in the body; and (3) decrease the length and severity of COVID-19 illness. The antibodies in this study cannot give you SARS-CoV-2.
Eligibility Criteria
- Age 18 years of age or older
- Currently pregnant
- Tested positive for SARS-CoV-2 (test occurred not more than 3 days prior to enrollment)
- Willing and able to provide written informed consent to participate
- Experiencing at least one symptom common of COVID-19 (onset no more than 7 days prior to enrollment):
- Are at home (not in the hospital) and have not been hospitalized for COVID-19
- Agreement to not participate in another clinical trial of an experimental treatment for COVID-19 during the study period
Other protocol-defined Inclusion/Exclusion criteria may apply.
More about this trial
Step 1: Visit ClinicalTrials.gov, identifier NCT04425629, to determine if this study is right for you.
Step 2: If you are interested in volunteering, complete our online survey or contact us by phone or email.
COVID-19 Clinical Research Center
Entrance A:
820 Minor Ave N.
Seattle, WA 98109
Directions
Entrance B:
1205 Aloha St.
Seattle, WA 98109
Directions